Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute, Egypt
M.D. Anderson Cancer Center
Yale University
University of Texas Southwestern Medical Center
Groupe Oncologie Radiotherapie Tete et Cou
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
Medical University of South Carolina
University of Pittsburgh
Providence Health & Services
University of Chicago
GlaxoSmithKline
Washington University School of Medicine
IO Biotech
University of Arkansas
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Dana-Farber Cancer Institute
Medical University of South Carolina
Karolinska University Hospital
Regeneron Pharmaceuticals
NRG Oncology
Fudan University
Eastern Cooperative Oncology Group
Washington University School of Medicine
University of Erlangen-Nürnberg Medical School
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
University of Cincinnati
Canadian Cancer Trials Group
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
AstraZeneca
Sichuan Enray Pharmaceutical Sciences Company
Eastern Cooperative Oncology Group
Regeneron Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
Gruppo Oncologico del Nord-Ovest
University of Massachusetts, Boston
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Seagen Inc.
Fulgent Pharma LLC.
University of Kentucky